On August 1st the group started a research collaboration with Bayer HealthCare on the investigation of protein-ligand-binding. Aim of this project is to test the capability of native mass spectrometry to serve as a tool for the high throughput screening of pharmaceutically-relevant compounds. From now on, Melanies research will be focused on this topic.